Drug intelligence / Profile preview

CNT202

Development stage: Preclinical
Lead developer: Connext
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Topical

Overview

CNT202 is a recombinant collagenase-based therapeutic being developed by CONNEXT for wound debridement. It functions by utilizing the enzymatic activity of collagenase to selectively degrade collagen within necrotic tissue, thereby facilitating the removal of non-viable tissue from wounds and promoting the healing process. As of early 2025, the candidate is in the preclinical/nonclinical stage of development.

Other names: Recombinant collagenase

Beyond the preview

Go deeper on CNT202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNT202.

Explore the full profile